Vaccine Adjuvants Market Size, Share, Growth, Trends and Application Analysis Report
by Susan Hill Business ConsultantThe
global vaccine adjuvants market is expected to reach USD
758.8 million by 2025, according to a new report by Grand View Research, Inc.
The significance of adjuvant research in the development of vaccines has
increased gradually due to inadequate immunogenicity of innovative vaccine
antigens. In addition, the growing focus on long-lasting immunization effect
against existing and emerging diseases is expected to boost the demand for
vaccine adjuvants.
Furthermore,
rising prevalence of cervical cancer is anticipated to boost the market.
According to NCBI, around 15,000 females die every year due to cervical cancer.
There are certain companies developing vaccine adjuvants for this type of
cancer in order to enhance the efficacy, such as AS04 adjuvant-adsorbed (human
papillomavirus vaccine) by GSK, which boosts the immune response for a longer
duration.
Further Key
Findings from the Report Suggest:
- Particulate
product type dominated the market in 2016 due to greater efficiency of vaccines,
presence of wide range of products, easier availability, and improved
safety
- Pathogen is
anticipated to be the fastest growing segment with a CAGR of 11.9% due to
the availability of naturally occurring pathogens used as adjuvants
- Among the route
of administration, intramuscular held the largest market share in 2016 due
to the high immune specificity of vaccines
- Infectious
disease segment dominated the market in 2016 by application, due to the
increasing prevalence of infectious diseases such as hepatitis A, B, C,
influenza, meningitis, and others
- Cancer is
expected to be the fastest growing application segment because of the
rising prevalence of cancer and growing R&D activities to treat
various types of cancer
- Geographically,
North America held the largest market share due to increase in favorable
government initiatives and presence of well-established healthcare
services.
- Asia Pacific is
estimated to be the fastest growing region over the forecast period with a
significant CAGR from 2017 to 2025 due to the presence of huge target
population and rise in disposable income
- Some of the key
players of the market include GlaxoSmithKline plc.; Novavax, Inc.;
Adjuvance Technologies, Inc.; SPI Pharma; Agenus, Inc.; CSL Limited;
InvivoGen; and Brenntag Biosector
- Most of the key
participants are focusing on strategies such as mergers & acquisitions,
collaborations, and expansion of their product portfolios
- In December
2015, SPI Pharma agreed to collaborate with Asahi Kasei Corporation. Both
the companies agreed to sell each other’s products in their respective
markets: Japan and North America.
Access full
research report on global vaccine adjuvants market:
www.grandviewresearch.com/industry-analysis/vaccine-adjuvants-market
Sponsor Ads
Created on Sep 10th 2019 04:28. Viewed 414 times.